PPAR Research / 2013 / Article / Tab 3

Clinical Study

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Table 3

Plasma apolipoprotein concentrations levels (mg/dL) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean, standard deviation, and 95% confidence interval (in parenthesis).

CKD patientsHealthy reference group
At entryAfter 6 weeksEstimated changeAt entryAfter 6 weeksEstimated change

Apo A-I141 (16)153 (21) +9%**145 (23)154 (20)+7%
Apo B126 (34)104 (31)−18%***105 (16)87 (17)−17%***
Apo B/Apo A-I0.9 (0.3) 0.7 (0.3)−24%***0.7 (0.2)0.6 (0.1) −22%***
Apo C-III16.6 (5.4)17.4 (3.9)+6%11.4 (2.4)11.1 (2.5)−3%
Apo C-III-HS9.1 (2.3)11.4 (3.8)+30%***8.3 (2.5)8.1 (2.3)+2%
Apo C-III-HP6.8 (3.0)5.7 (2.6)−13%**3.6 (1.0)3.2 (1.2)−14%**
Apo C-III ratio1.5 (0.7)2.5 (1.6)+55%**2.3 (0.9)2.9 (1.6)+19%
Apo A-I/Apo C-III9.0 (2.0)9.2 (2.0)+9%13.2 (2.7)14.3 (2.5)+2%
Apo E7.8 (2.9)8.2 (2.6)+5%5.5 (1.2)6.0 (1.8)+8%

P < 0.01 and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.